ACCESS
ACCESS: A Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Patients with Hematologic Malignancies
What's the purpose of the trial?
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.
Accepting patients
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Busulfan is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body.
- Fludarabine is a chemotherapy agent used in the treatment of cancer.
- Radiation is used to fight may types of cancer including multiple myeloma. Cancer cells multiply faster than normal cells in the body. Radiation is most harmful to quickly growing cells, so radiation therapy damanges cancer cells more than normal cells. This stops cancer cells from growing and dividing and leads to cell death.
- Melphalan is a chemotherapy medication used in the treatment of multiple myeloma.
- Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.